ACAA2, a fatty acid metabolism enzyme, inversely correlates with cetuximab resistance, particularly in KRAS-mutant CRC, suggesting its role in metabolic adaptation and therapy response regulation (59). This evidence concerns the gene KRAS and colorectal carcinoma.